Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:43:05 EDT Fri 03 May 2024
Enter Symbol
or Name
USA
CA



News for U:SCYX from 2023-05-04 to 2024-05-03 - 52 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-30 16:05U:SCYXNews ReleaseSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
2024-04-09 16:05U:SCYXNews ReleaseSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2024-03-28 16:01U:SCYXNews ReleaseSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
2024-01-30 16:05U:SCYXNews ReleaseSCYNEXIS to Participate in Guggenheim ¢ € ™s 6th Annual Biotechnology Conference
2024-01-29 17:15U:SCYXNews ReleaseSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
2024-01-05 08:30U:SCYXNews ReleaseSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 ¢ € “ 27, in Milan, Italy
2024-01-04 17:38U:SCYXNews ReleaseSCYX DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYX
2024-01-03 15:40U:SCYXNews ReleaseSCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
2023-12-25 14:38U:SCYXNews ReleaseROSEN, LEADING INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-12-22 20:36U:SCYXNews ReleaseROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-12-19 03:31U:SCYXNews ReleaseNATIONALLY RANKED ROSEN LAW FIRM Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-12-16 20:00U:SCYXNews ReleaseROSEN, A LONGSTANDING LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-12-11 06:33U:SCYXNews ReleaseIMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
2023-12-10 10:02U:SCYXNews ReleaseSCYX Class Action Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-09 20:00U:SCYXNews ReleaseROSEN, A LEADING LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-12-09 02:01U:SCYXNews ReleaseROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-12-08 11:26U:SCYXNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
2023-12-08 07:16U:SCYXNews ReleaseSCYX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-08 05:06U:SCYXNews ReleaseIMPORTANT DEADLINE REMIDNER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
2023-12-07 07:17U:SCYXNews ReleaseSCYX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-07 05:32U:SCYXNews ReleaseINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
2023-12-06 07:20U:SCYXNews ReleaseSCYX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-06 07:02U:SCYXNews ReleaseFINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
2023-12-05 07:19U:SCYXNews ReleaseSCYX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-04 07:05U:SCYXNews ReleaseIMPORTANT DEADLINE REMINDER: The Schall Law Firm Reminds Investors in SCYNEXIS, Inc. with Losses to Contact the Firm
2023-12-03 07:21U:SCYXNews ReleaseSCYX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-03 06:42U:SCYXNews ReleaseSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of In Excess of $100,000 to Contact the Firm
2023-12-02 11:20U:SCYXNews ReleaseSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
2023-12-01 07:17U:SCYXNews ReleaseSCYX Shareholder Alert: Bronstein, Gewirtz & Grossman LLC Reminds Scynexis, Inc.Investors with Substantial Losses to Contact the Firm!
2023-12-01 06:04U:SCYXNews ReleaseIMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
2023-11-30 03:30U:SCYXNews ReleaseROSEN, A LEADING AND RANKED FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-28 22:01U:SCYXNews ReleaseROSEN, NATIONAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-27 00:01U:SCYXNews ReleaseROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-25 02:30U:SCYXNews ReleaseROSEN, LEADING TRIAL ATTORNEYS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-23 02:00U:SCYXNews ReleaseROSEN, NATIONAL INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-21 21:00U:SCYXNews ReleaseROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-20 18:30U:SCYXNews ReleaseROSEN, SKILLED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-18 04:00U:SCYXNews ReleaseROSEN, A RESPECTED AND LEADING FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-17 03:00U:SCYXNews ReleaseROSEN, LEADING TRIAL ATTORNEYS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-13 22:01U:SCYXNews ReleaseROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages SCYNEXIS, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
2023-11-13 17:18U:SCYXNews ReleaseSCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-24 08:00U:SCYXNews ReleaseSCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
2023-10-16 08:00U:SCYXNews ReleaseSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
2023-09-27 20:31U:SCYXNews ReleaseSCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME ‚ ® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ƒ Ÿ-lactam drug substance
2023-08-28 08:00U:SCYXNews ReleaseSCYNEXIS to Participate in September Investor Conferences
2023-08-14 16:30U:SCYXNews ReleaseSCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-20 09:58U:SCYXNews ReleaseSCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
2023-06-21 07:00U:SCYXNews ReleaseSCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
2023-06-15 16:10U:SCYXNews ReleaseSCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference
2023-05-19 09:23U:SCYXNews ReleaseWBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
2023-05-12 08:00U:SCYXNews ReleaseSCYNEXIS Reports Closing of Exclusive License Agreement with GSK for ‚  BREXAFEMME ‚ ® (Ibrexafungerp Tablets)
2023-05-11 07:00U:SCYXNews ReleaseSCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update